UPDATE: Oppenheimer Downgrades Seattle Genetics (SGEN) to Perform; Valuation Call
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Price: $228.74 --0%
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - September 7, 2012 9:45 AM EDT)
Oppenheimer downgraded Seattle Genetics (NASDAQ: SGEN) from Outperform to Perform. PT lowered by $1 to $27.
Analyst, Boris Peaker, said, "Our downgrade is largely based on valuation. We believe that at the current price, there is more downside risk than near-term upside potential. However, we believe that the long-term value of the platform remains intact, which is why we are maintaining a PT. The $1 change in our target is largely immaterial and is due to changes in our financial model. We would look to revisit the stock if it falls to the low $20s. Given the current valuation and the volatile short interest, we believe a drop in valuation is possible if ADCETRIS misses investor expectations."
FY12 EPS estimate lowered from (0.55) to (0.60) and FY13 from (0.31) to (0.46).
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $29.68 yesterday.
Oppenheimer downgraded Seattle Genetics (NASDAQ: SGEN) from Outperform to Perform. PT lowered by $1 to $27.
Analyst, Boris Peaker, said, "Our downgrade is largely based on valuation. We believe that at the current price, there is more downside risk than near-term upside potential. However, we believe that the long-term value of the platform remains intact, which is why we are maintaining a PT. The $1 change in our target is largely immaterial and is due to changes in our financial model. We would look to revisit the stock if it falls to the low $20s. Given the current valuation and the volatile short interest, we believe a drop in valuation is possible if ADCETRIS misses investor expectations."
FY12 EPS estimate lowered from (0.55) to (0.60) and FY13 from (0.31) to (0.46).
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $29.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities
- Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
